Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Antibody therapeutics have demonstrated transformative impacts on improving the quality of life of millions of patients, whereas advances in antibody discovery technologies have imposed a significant production challenge for the generation of a large diversity of therapeutic antibody candidates. A demand for the rapid production of dozens of purified antibodies in 10-mg quantities is entailed for functional screening and molecular assessment studies. Here, we present a robust semi-automated production protocol that bridges the gap between miniaturized high-throughput screenings and conventional custom-scale workflows. This methodology and workflow utilize a simple high-titer transient Chinese hamster ovary (CHO) cell host–CHO4Tx® expression system, a procedure of magnetic protein-A bead in-culture antibody capturing, and a semi-automated purification process with the GenScript AmMagTM SA Plus system. This production protocol has been proven to be robust and valuable for the routine production of dozens of antibody constructs per week in sufficient quality and quantity for cell-based and biophysical studies.